F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of neurodegeneration.
Genetic analysis of six subjects revealed an absence of myeloid differentiation primary response 88 (MYD88) or cluster ... of a better response to BTK inhibitors. Sellas Life Sciences CEO and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback